Compass Therapeutics (CMPX) H.C. Wainwright 4th Annual BioConnect Investor Conference summary

Technology and pipeline overview

• Focuses on monoclonal and bispecific antibodies for oncology, with four clinical-stage drugs, including a DLL4 VEGF-A bispecific as the lead asset.

• StitchMabs platform enables discovery of synergistic bispecific antibodies, supporting ongoing discovery research.

Lead asset: Tovecimig clinical data and strategy

• Tovecimig targets VEGF-A and DLL4, aiming to overcome resistance seen with VEGF-targeted therapies.

• In the pivotal COMPANION-002 phase II/III study for second-line biliary tract cancer, tovecimig plus paclitaxel showed a hazard ratio of 0.44 for PFS and more than tripled response rates versus control.

• Crossover design allowed patients on control to receive tovecimig, with those crossing over achieving median OS of 12.8 months.

• Planning FDA meeting in late July/early August and preparing for BLA submission later this year.

Insights from crossover and future indications

• Crossover patients had improved PFS post-crossover (1.9 to 3.5 months), suggesting a unique effect of tovecimig after paclitaxel.

• Investigating whether paclitaxel primes tumors for tovecimig, with implications for future trials in gastric and ovarian cancers.

• Considering a two-month paclitaxel lead-in for future gastric cancer studies.